Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry

(2012) Lene Dreyer et al.   ANNALS OF THE RHEUMATIC DISEASES

HIF-1α Acts Downstream of TNF-α to Inhibit Vasodilator-Stimulated Phosphoprotein Expression and Modulates the Adhesion and Proliferation of Breast Cancer Cells

(2012) Ke Su et al.   DNA AND CELL BIOLOGY

Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population

(2012) L. K. Mercer et al.   RHEUMATOLOGY

Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents

(2011) Pauline Raaschou et al.   ARTHRITIS AND RHEUMATISM

Proinflammatory Cytokines in Breast Cancer: Mechanisms of Action and Potential Targets for Therapeutics

(2010) Jodi E. Goldberg et al.   CURRENT DRUG TARGETS

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

(2010) Johan Askling et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register

(2010) W. G. Dixon et al.   ARTHRITIS CARE & RESEARCH

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT

(2010) Anja Strangfeld et al.   ARTHRITIS RESEARCH & THERAPY

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?

(2009) Johan Askling et al.   ARTHRITIS AND RHEUMATISM

Risk of cancer among rheumatoid arthritis patients in California

(2009) Arti Parikh-Patel et al.   CANCER CAUSES & CONTROL

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

(2008) J P Leombruno et al.   ANNALS OF THE RHEUMATIC DISEASES